Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 29, 2026

Corteva Announces Board of Directors for Advanced Seed and Genetics Spin-Off Vylor

View original at finance.yahoo.com
Corteva Announces Board of Directors for Advanced Seed and Genetics Spin-Off Vylor Karen Grimes to be Chair; separation on track for 4Q 2026 INDIANAPOLIS, June 29, 2026 /PRNewswire/ -- Corteva Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Vylor separation remains on track for the fourth quarter of 2026.

    60% confidence

  • Vylor's innovation engine will be anchored in the agriculture industry's most elite germplasm and transformative biotech, leveraging next generation scientific expertise in gene editing and molecular breeding.

    60% confidence

  • Vylor will be a company dedicated to leveraging its expertise in advanced seed and genetics to help farmers feed and fuel the world, focused on accelerating the company's growth and impact and delivering results for shareholders.

    60% confidence

  • A search is ongoing for at least one additional Vylor board member beyond the initial seven announced.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com
Corteva Announces Board of Directors for Advanced Seed and Genetics Spin-Off Vylor — Source | Via News | ViaNews Market